Evidence map›Paper›PMID 41454741›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Metformin-Based Covalent Organic Frameworks With Excellent Biosafety and High Efficiency against Pathogenic Microorganisms.

Jia-Yi Liu, Hong Jiang, Lei Ma, Jin-Yi Yu, Ming-Yi Yang, Hao-Ru Wang, Jun-Yuang Tang, Shengfeng Huang, Wei Yi, Meng Lu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jia-Yi LiuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, P. R. China.
Hong JiangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, P. R. China.
Lei MaGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, P. R. China.
Jin-Yi YuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, P. R. China.
Ming-Yi YangGuangdong Provincial Key Laboratory of Carbon Dioxide Resource Utilization, School of Chemistry, South China Normal University, Guangzhou, P. R. China.
Hao-Ru WangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P. R. China.
Jun-Yuang TangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, P. R. China.
Shengfeng HuangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, P. R. China.
Wei YiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, P. R. China.
Meng LuGuangdong Provincial Key Laboratory of Carbon Dioxide Resource Utilization, School of Chemistry, South China Normal University, Guangzhou, P. R. China.
Ya-Qian LanGuangdong Provincial Key Laboratory of Carbon Dioxide Resource Utilization, School of Chemistry, South China Normal University, Guangzhou, P. R. China.ORCID https://orcid.org/0000-0002-2140-7980
Xu-Jia HongGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, P. R. China.

Funding

Affiliated Hospital of Traditional Chinese Medicine of Guangzhou Medical University 2024xk06Guangdong Basic and Applied Basic Research Foundation 2025B1515020049Guangzhou Science and Technology Fund 2025A03J3420National Natural Science Foundation of China 22201083National Natural Science Foundation of China 22225109National Natural Science Foundation of China 22571099Natural Science Foundation of Guangdong Province 2025A1515012133
6 · The paper itself

Abstract

The escalating public health security crisis caused by pathogenic microorganisms and the worsening antibiotic resistance urgently demand the development of antimicrobial materials with high efficiency and safety. Covalent organic frameworks (COFs) exhibit significant potential in photocatalytic antibacterial applications, but face challenges such as insufficient biosafety and difficulties in application translation. In this work, we first report two metformin-based photoactive cationic MCOFs engineered for synergistic functionality and safety. They exhibit broad-spectrum light absorption, efficient charge separation, and generate multiple ROS via Type I/II photodynamic, achieving >99 % inactivation of bacteria/viruses. Excellent biocompatibility with LD

Indexed as

Anti-Bacterial AgentsMetal-Organic FrameworksMetforminAnimalsHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsAnti-Bacterial AgentsMetal-Organic FrameworksMetforminbiosafetycovalent organic frameworksmetforminphotoactivity

Identifiers

PMID41454741
PMCPMC12970249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.